Merus/MRUS

$40.31

-2.32%
-
1D1W1MYTD1YMAX

About Merus

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Ticker

MRUS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sven Lundberg

Employees

172

Headquarters

Utrecht, Netherlands
Website
merus.nl

Merus Metrics

BasicAdvanced
$2.42B
Market cap
-
P/E ratio
-$2.99
EPS
1.12
Beta
-
Dividend rate
$2.42B
1.12331
$52.04
$18.21
568.08K
5.338
-37.24%
-51.36%
-45.3%
55.113
6.697
6.831
5.68%
-4.14%
13.64%

What the Analysts think about Merus

Analyst Ratings

Majority rating from 14 analysts.
Buy

Price Targets

Average projection from 12 analysts.
50.91% upside
High $69.00
Low $52.00
$40.31
Current price
$60.83
Average price target

Merus Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-675.28% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$8.9M
-19.09%
Net income
$-60.1M
161.3%
Profit margin
-675.28%
222.96%

Merus Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 41.01%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.86
-$0.66
-$0.43
-$1.04
-
Expected
-$1.02
-$0.88
-$0.73
-$0.74
-$0.81
Surprise
-15.54%
-24.62%
-41.37%
41.01%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Merus stock?

Merus (MRUS) has a market cap of $2.42B as of April 17, 2024.

What is the P/E ratio for Merus stock?

The price to earnings (P/E) ratio for Merus (MRUS) stock is 0 as of April 17, 2024.

Does Merus stock pay dividends?

No, Merus (MRUS) stock does not pay dividends to its shareholders as of April 17, 2024.

When is the next Merus dividend payment date?

Merus (MRUS) stock does not pay dividends to its shareholders.

What is the beta indicator for Merus?

Merus (MRUS) has a beta rating of 1.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Merus stock price target?

The target price for Merus (MRUS) stock is $60.83, which is 50.91% above the current price of $40.31. This is an average based on projections from 12 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Merus stock

Buy or sell Merus stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing